News

ASX ANNOUNCEMENT MINNEAPOLIS, MN – Admedus Limited (ASX:AHZ) (Company or Admedus) today announced that it has entered into an agreement with Partners for Growth (PFG) for a secured debt facility of up to AUD $10 million. Based in the San Francisco Bay area, PFG is a partnership that provides capital funding debt solutions to private

SOUTH SAN FRANCISCO, Calif., July 27, 2017 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that it has entered into a venture loan and security agreement with Horizon Technology Finance Corporation (NASDAQ: HRZN), which provides Titan

~ Financing Comprised of $50 Million Credit Facility and $3 Million Equity Investment ~ ~ Simultaneously Retiring Existing Debt ~ ~ Funds Received at Close Provide Sufficient Cash Under Current Operating Plan to Extend Cash Runway to Positive Cash Flow ~ DUBLIN, Ireland and TREVOSE, Pa., July 17, 2017 (GLOBE NEWSWIRE) —  Strongbridge Biopharma plc, (Nasdaq:SBBP),

SUNNYVALE, CA–(Marketwired – May 23, 2017) – Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s health, today announced that it has entered into a senior credit facility with affiliates of CRG LP to retire its existing credit facility and provide additional capital for the company. The new credit facility consists

Term Loans Support Commercialization in Europe and U.S. Regulatory Clearance and Market Development May 10, 2017 04:02 PM Eastern Daylight Time RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT:TRXC) (the “Company”), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has entered into a

Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida Infections Well-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients Evidence of Efficacy and Lower Relapse Rates versus Standard of Care in VVC Patients Strong Cash Position to Accelerate and Expand Development of SCY-078 in Multiple Indications   JERSEY

MINNEAPOLIS, Aug. 9, 2016 /PRNewswire/ — CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility.  CVRx plans to use the proceeds for the primary purposes of completing the Baroreflex Activation Therapy for Heart Failure Pivotal Clinical Trial (BeAT-HF) and expanding its global commercial activities.